- Home
- TOL vs UTHR Comparison
TOL vs UTHR Comparison
Compare TOL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- UTHR
- Stock Information
- Founded
- TOL 1967
- UTHR 1996
- Country
- TOL United States
- UTHR United States
- Employees
- TOL N/A
- UTHR N/A
- Industry
- TOL Homebuilding
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- TOL Consumer Discretionary
- UTHR Health Care
- Exchange
- TOL Nasdaq
- UTHR Nasdaq
- Market Cap
- TOL 13.8B
- UTHR 13.8B
- IPO Year
- TOL N/A
- UTHR 1999
- Fundamental
- Price
- TOL $133.21
- UTHR $458.23
- Analyst Decision
- TOL Buy
- UTHR Buy
- Analyst Count
- TOL 15
- UTHR 15
- Target Price
- TOL $151.20
- UTHR $459.60
- AVG Volume (30 Days)
- TOL 1.3M
- UTHR 845.8K
- Earning Date
- TOL 08-19-2025
- UTHR 10-29-2025
- Dividend Yield
- TOL 0.75%
- UTHR N/A
- EPS Growth
- TOL N/A
- UTHR 17.94
- EPS
- TOL 13.61
- UTHR 25.63
- Revenue
- TOL $10,876,787,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- TOL $0.38
- UTHR $13.71
- Revenue Next Year
- TOL N/A
- UTHR $5.38
- P/E Ratio
- TOL $9.78
- UTHR $17.82
- Revenue Growth
- TOL 3.26
- UTHR 17.62
- 52 Week Low
- TOL $86.67
- UTHR $266.98
- 52 Week High
- TOL $169.52
- UTHR $458.94
- Technical
- Relative Strength Index (RSI)
- TOL 43.06
- UTHR 73.07
- Support Level
- TOL $137.95
- UTHR $415.00
- Resistance Level
- TOL $143.86
- UTHR $442.01
- Average True Range (ATR)
- TOL 3.20
- UTHR 13.27
- MACD
- TOL -0.72
- UTHR 0.14
- Stochastic Oscillator
- TOL 5.97
- UTHR 99.14
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.